Literature DB >> 20216235

Assessment of bone mineral density and risk factors in children completing treatment for acute lymphoblastic leukemia.

Adalet Meral Gunes1, Erkan Can, Halil Saglam, Yeşim Ozarda Ilçöl, Birol Baytan.   

Abstract

BACKGROUND: Reduced bone mineral density and increased fracture risk have been reported in children with cancer. In this study, we aimed to determine the growth and bone mineral density (BMD) of the children off chemotherapy for acute lymphoblastic leukemia, and the probable risk factors. PROCEDURE: The age, anthropometric measurements, lumbar spine BMDs were recorded in 70 children. The risk factors on BMD; daily calcium intake, the time interval from the completion of the chemotherapy, cranial radiotherapy, cumulative steroid dose, decrease in physical activity were investigated. Serum calcium, phosphate, alkaline phosphates, magnesium, insulin-like growth factor-1 (IGF-1) and 25 (OH) vitamin D levels were determined.
RESULTS: The mean height percentile at the time of diagnosis was decreased from the value of 53 to a value of 47 at the beginning of the study (P=0.071). Of them; 44% had osteoporosis, 41% had osteopenia, and the rest had normal BMD. BMD z-scores were decreased during the first 2 years from the completion of the treatment. There was a positive correlation between BMD z-scores and daily calcium intake (CC=0.366, P=0.0015). A negative correlation was determined between the time spent on TV and computers and BMD z-scores (CC=-0.464, P=0.0019). Serum IGF-1 and 25 (OH) vitamin D levels of patients were significantly lower than controls (P=0.033).
CONCLUSIONS: Our data revealed that 85% of the survivors had bone mineralization defect. BMDs and z scores were decreased during the first 2 years from the completion of the treatment and then gradually began to increase. The most important risk factor for decreased BMD was low daily calcium intake. Therefore, patients and their families should be encouraged to take sufficient amount of calcium. Prophylactic vitamin D may also be supplemented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216235     DOI: 10.1097/MPH.0b013e3181d32199

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  12 in total

1.  Evaluating the Effect of Induction Chemotherapy on Bone Metabolizing Nutrients in Patients of Acute Lymphoblastic Leukemia.

Authors:  Aamir Khan; Junaid Zeb; Nazish Farooq; Nayab Farid; Rifaq Zeb; Muhammad Shoaib
Journal:  Cureus       Date:  2022-05-27

2.  Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study.

Authors:  J G Gurney; S C Kaste; W Liu; D K Srivastava; W Chemaitilly; K K Ness; J Q Lanctot; R P Ojha; K A Nottage; C L Wilson; Z Li; L L Robison; M M Hudson
Journal:  Pediatr Blood Cancer       Date:  2014-02-28       Impact factor: 3.167

3.  Reduced bone density in patients with autosomal dominant hyper-IgE syndrome.

Authors:  Oded Scheuerman; Vered Hoffer; Avner Herman Cohen; Cristina Woellner; Bodo Grimbacher; Ben-Zion Garty
Journal:  J Clin Immunol       Date:  2013-04-19       Impact factor: 8.317

4.  Bone turnover in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  Mitchell A Watsky; Laura D Carbone; Qi An; Cheng Cheng; Elizabeth A Lovorn; Melissa M Hudson; Ching-Hon Pui; Sue C Kaste
Journal:  Pediatr Blood Cancer       Date:  2014-03-20       Impact factor: 3.167

Review 5.  Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis.

Authors:  M Farsinejad-Marj; P Saneei; A Esmaillzadeh
Journal:  Osteoporos Int       Date:  2015-11-10       Impact factor: 4.507

6.  Prevalence of vitamin D insufficiency in survivors of childhood cancer.

Authors:  Abha Choudhary; Joanne Chou; Glenn Heller; Charles Sklar
Journal:  Pediatr Blood Cancer       Date:  2012-11-28       Impact factor: 3.167

7.  Modifiable risk factors associated with bone deficits in childhood cancer survivors.

Authors:  Lynda E Polgreen; Anna Petryk; Andrew C Dietz; Alan R Sinaiko; Wendy Leisenring; Pam Goodman; Lyn M Steffen; Joanna L Perkins; Donald R Dengel; K Scott Baker; Julia Steinberger
Journal:  BMC Pediatr       Date:  2012-03-28       Impact factor: 2.125

8.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

9.  Bone mineral density, thyroid function, and gonadal status in young adult survivors of childhood cancer.

Authors:  Eryk Latoch; Katarzyna Muszyńska-Rosłan; Agata Panas; Anna Panasiuk; Beata Rutkowska-Żelazowska; Jerzy Konstantynowicz; Maryna Krawczuk-Rybak
Journal:  Contemp Oncol (Pozn)       Date:  2014-10-18

10.  Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations.

Authors:  Jenneke E van Atteveld; Iris E Verhagen; Marry M van den Heuvel-Eibrink; Hanneke M van Santen; Inge M van der Sluis; Natascia Di Iorgi; Jill H Simmons; Leanne M Ward; Sebastian J C M M Neggers
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.